CONTACT US for more information
Humanized Xenograft Models
Bridging Human Immunity and Cancer In Vivo
Humanized Xenograft Models represent the pinnacle of preclinical modeling for immunotherapy development. These models go a step beyond standard xenografts by not only hosting human tumor cells but also by being reconstituted with key components of the human immune system. This is achieved by transferring human hematopoietic stem cells (CD34+) or human peripheral immune cells into immunodeficient mice. The result is a mouse with a functional human immune system operating within a tumor microenvironment.
Immunotherapy in Its Most Relevant Context
The central objective of humanized xenograft models is to create an in vivo environment that allows for an accurate and relevant evaluation of therapies that directly interact with the human immune system. This is indispensable for the development of new immunotherapies, where efficacy and safety are intrinsically dependent on the interplay between the drug, the patient’s immune cells, and the tumor.
The Ultimate Platform for Advanced Immuno-oncology
Evaluation of CAR-T (Chimeric Antigen Receptor T-cell therapies)
They allow testing the ability of CAR-T cells to recognize, attack, and eliminate human tumor cells in an environment with a human immune system.
Study of Bispecific Antibodies (BiTEs) and Monoclonal Antibodies
They are ideal for evaluating the ability of BiTEs to «engage» T cells and tumor cells, or the function of monoclonal antibodies that mediate immunological effects (like ADCC or ADCP) through human immune cells.
Investigation of CELMoDs (CRBN E3 Ligase Modulating Drugs)
They enable the study of how these drugs, which act through cereblon-mediated protein degradation, modulate the immune response and the elimination of tumor cells.
Analysis of Immune-Tumor Engagement In Vivo
They offer the unique opportunity to observe and quantify how human immune cells interact with the tumor, migrate to the tumor site, and exert their anti-tumor function in a physiological environment.
Discovery of Immune Resistance Mechanisms
They help unravel why some tumors develop resistance to immunotherapy and how these resistances can be overcome.
Optimization of Immunotherapeutic Combination Strategies
They allow for the evaluation of combined therapies involving different immunological mechanisms, seeking synergies to improve patient response.
